Skip to main content
. 2021 Jan 21;19:860–868. doi: 10.1016/j.csbj.2021.01.025

Fig. 4.

Fig. 4

TNFRSF9 expression level in tumor-infiltrating regulatory T cells (TI-Tregs) is predictive of clinical outcomes in anticancer treatment. (a-b) Kaplan-Meier analysis curves by high (top 30%) and low (bottom 30%) expression levels of FOXP3 (a), expression level of TNFRSF9 normalized by that of FOXP3 (b) in tumor samples from The Cancer Genome Atlas-lung adenocarcinoma (TCGA-LUAD) and TCGA-lung squamous cell carcinoma (LUSC). (c-d) Kaplan-Meier analysis curves by high (top 40%) and low (bottom 40%) expression levels of FOXP3 (a), expression level of TNFRSF9 normalized by that of FOXP3 (b) in tumor samples from Swedish cohort of lung cancer (GSE81089) (e-f) Waterfall plots showing expression changes from baseline (median) for FOXP3 (e) and TNFRSF9 normalized by FOXP3 (f) in tumor samples from patients with non-small cell lung cancer (NSCLC) treated by anti-PD-1 inhibitors (GSE135222).